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Use of cinacalcet and sunitinib 
to treat hypercalcaemia due to a 
pancreatic neuroendocrine tumor
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SUMMARY
Neuroendocrine tumors (NETs) can secrete hormones, including ectopic secretions, but they have 
been rarely associated with malignant hypercalcemia. A 52-year-old man with a history of diabetes 
mellitus was diagnosed with a pancreatic tumor. A pancreatic biopsy confirmed a well-differentiated 
pancreatic NET (pNET). The patient subsequently developed liver metastasis and hypercalcemia with 
high 1,25 OH vitamin D and suppressed parathyroid hormone (PTH) levels. Hypercalcemia was re-
fractory to chemotherapy, intravenous saline fluids, diuretics, calcitonin and zoledronate. Cinacalcet 
administration (120 mg/day) resulted in a significant calcium reduction. Hypocalcemia was observed 
when sunitinib was added three months later and cinacalcet was stopped. Subsequently, the cal-
cium and PTH levels normalized. After six months, we observed 20% shrinkage of the pancreatic 
tumor and necrosis of a liver metastasis. Cinacalcet is an allosteric activator of the calcium receptor 
agonist, and it is used for severe hypercalcemia in patients with primary (benign and malignant) hy-
perparathyroidism. In this patient, cinacalcet demonstrated a calcium lowering effect, normalized hy-
pophosphatemia, and improved the clinical condition of the patient. The mechanism through which 
cinacalcet improved PTH-rp mediated hypercalcemia is still unclear, but studies have suggested that 
a potential mechanism is the activation of calcitonin secretion. Sunitinib is an oral multi-targeted 
tyrosine kinase inhibitor used to treat advanced pNETs. The hypocalcemic effects of sunitinib have 
not been previously described in a patient with pNET. Here, we report for the first time the successful 
combination of cinacalcet and sunitinib in the treatment of a pNET patient presenting with malignant 
hypercalcemia. 
1 Service d’ Endocrinologie. 
CHU de Liège, Belgium
2 Servicio de Endocrinología y 
Nutrición, Hospital Universitari i 
Politècnic La Fe, Valencia, Spain
3 Unidad de Gestión Clínica 
de Endocrinología y Nutrición, 
Hospital Universitario de Valme, 
Área de Gestión Sanitaria 
Sur de Sevilla, Spain
4 Service de Gastroentérologie, 
CHU de Liège, Belgium
5 Department of Medicine, 
Division of Hematology, CHU 





Rue de l’Hôpital B35






H ypercalcemia of malignancy (HCM) develops as a paraneoplastic process in several types 
of cancers, such as lymphoma, breast cancer, and 
lung cancer (1), but it has rarely been described in 
neuroendocrine tumors (NETs) (1-3). In the setting 
of neuroendocrine tumors (NETs), HCM is associated 
with advanced disease, poor prognosis, and decreased 
survival rates (4,5). The most common cause of HCM 
is the tumor secretion of parathyroid hormone related 
peptide or PTH-rp (PTH-rp-oma) (2,5). Pancreatic 
NETs are typically pluripotent, and they have the 
ability to produce several types of hormones, including 
PTH-rp and calcitonin (2-6). When feasible, primary 
tumor surgery should be performed to normalize 
hypercalcemia. Unfortunately, the conventional 
hypocalcemic treatment options (e.g., bisphosphonates, 
corticosteroids, diuretics, hyper hydration) do not seem 
to improve patient survival in these cases. Here, we 
report, for the first time, the successful combination of 
cinacalcet and sunitinib in a pNET patient presenting 
with malignant hypercalcemia. In this case, in the 
setting of pancreatic NET, hypercalcemia associated 
with hypophosphatemia and suppressed PTH levels 
were highly likely due to PTH-rp secretion, although 
serum PTH-rp levels could not be measured. 
CASE REPORT
A 52-year-old-man with a history of diabetes 
mellitus and smoking presented with abdominal pain 
and asthenia for one year. Abdominal computed 
tomography (CT) revealed a 15 cm mass involving the 
pancreas and the retroperitoneum, with splenic and 
hepatic carcinomatosis. The histology of the pancreatic 
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AE1/AE3, synaptophysin, and CD56. Chromogranin 
immunostaining was negative. The Ki-67 labelling 
index was 2%. Somatostatin-receptor scintigraphy 
(octreoscan) detected areas of pathologic uptake in the 
liver and pancreas, whereas bone scintigraphy did not 
reveal any skeletal metastatic deposits. Hypercalcemia 
was diagnosed with calcium and ionized calcium levels 
of 3.54 mmol/L (2.15-2.6) and 1.55 mmol/L (1.14-
1.3), respectively. Other bone metabolism abnormalities 
included hypophosphatemia levels of 0.42 mmol/L 
(0.74-1.51), PTH levels of < 4 ng/mL (12-58), 1-25 
OH vitamin D levels of 100 pg/mL (< 85), 25 OH 
vitamin D levels of 9 ng/ml (> 30) and calcitonin (as 
a tumor maker) levels of 1116 ng/mL (< 10). The 
chromogranin A level was 26.9 UI/L (< 23). Urine 
analysis showed hypercalciuria and hyperphosphaturia. 
A bone density analysis showed mild cortical and 
femoral osteopenia. Because surgery was not feasible, 
the patient underwent treatment with several cycles of 
streptozotocin-adriamycin and FOLFOX. The tumor 
mass and calcium levels were partially controlled (2.61 
mmol/L), whereas the PTH concentration remained 
low (19 ng/mL). Three months later, the patient’s 
calcitonin levels were 29 ng/mL, and his calcium level 
increased again (2.94 mmol/L), whereas his PTH level 
was < 2 pg/mL. Treatment with octreotide LAR 30 mg 
sc every 4 weeks was introduced for 3 months, without 
any remarkable clinical impact. Hypercalcemia (total 
calcium 3.17 mmol/L) was refractory to intravenous 
saline fluids, diuretics, recombinant calcitonin, and 
zoledronate. Therefore, compassionate treatment with 
oral cinacalcet (120 mg/day) was attempted. The 
patient’s calcium level gradually decreased from 3.17 to 
2.87 mmol/L and later to 2.65 mmol/L (Figure 1). The 
phosphatemia normalized from 0.42 mmol/L to 0.84 
mmol/L during the cinacalcet treatment. PTH, 1,25 
OH vitamin and calcitonin levels, as well as the tumor 
size, remained unchanged. After a significant clinical 
improvement following a three months of cinacalcet 
treatment (Mimpara© 120 mg per day), sunitinib was 
added (Sutent© 35.7 mg per day) for tumor control 
(Figure 1). Both drugs were well tolerated, without 
any side effects.
One month after beginning the combined 
treatment, the patient’s calcium level decreased to 2.12 
mmol/L. Because of the hypocalcemia, the PTH level 
increased to 78 pg/mL, requiring discontinuation 
of cinacalcet. The calcitonin and 1,25 OH vitamin D 
levels normalized, whereas the positron emission 
tomography (PET) scan revealed a 20% shrinkage of 
the pancreatic tumor and necrosis of a metastasis in 
the VII hepatic segment following the cinacalcet and 
sunitinib treatment. Currently the patient is alive 
and still being treated with sunitinib. According to 
the RECIST (Response Evaluation Criteria in Solid 
Tumors) criteria, the patient has had stable disease for 
the last four years.
Figure 1. Serum calcium levels at the time of diagnosis, during the 
cinacalcet treatment (Mimpara© 120 mg/day PO), and during the 
combined treatment with Mimpara (120 mg/day) and sunitinib (Sutent© 
35.7 mg/day). Cinacalcet was stopped when the calcium levels reached 
2.12 mmol/L. The red line represents the upper normal calcium levels. 
The patient, whose calcium parameters remain normal, is currently being 
























HCM occurs in approximately 30% of all cancer 
patients. HCM may be caused by different mechanisms, 
including the production of parathyroid hormone-
related peptide (PTH-rp), which is the most frequent 
cause (1-4), and/or 1,25 OH vitamin D by tumor 
cells. In addition, ectopic PTH secretion can rarely 
occur (1-4). NETs often produce ectopic hormone 
secretions, but they are rarely associated with HCM 
(2,5). In this case, an osteolytic lesion and a PTH-
dependent mechanism of hypercalcemia were excluded. 
Unfortunately, we could not determine the PTH-rp 
levels of our patient, and no tumor specimen was 
available for PTH-rp studies. Therefore, it remains 
unproven whether PTH-rp hypersecretion was (at least 
partially) responsible for the hypercalcemia in this case.
Several treatment options are available to manage 
hypercalcemia in cancer patients (5-9). The extracellular 
volume must be restored with intravenous saline fluids 
because patients are frequently volume depleted (1). 
In addition, high diuretic doses can increase urinary 
calcium excretion levels (7). In addition, gallium nitrate, 
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cancer-related hypercalcemia (3). Glucocorticoids are 
frequently used to treat hypercalcemia in hematological 
malignancies. Intravenous bisphosphonates can be 
effective in treating HCM, and they have demonstrated 
extended durations of action and low rates of acute 
phase reaction symptoms (1-3). Denosumab, a human 
monoclonal antibody binding RANKL that inhibits 
osteoclast maturation and activation, is used to treat 
osteoporosis. Denosumab has been approved to treat 
HCM in the United States of America (USA), and it 
should be used in bisphosphonate resistant cases. It has 
been used to treat bisphosphonate-refractory HCM (8).
Cinacalcet is an oral drug that acts as a calcimimetic 
by activating the calcium-sensing receptor (CaSR). 
It is used to treat secondary hyperparathyroidism in 
chronic kidney disease and for severe hypercalcemia 
in patients with primary hyperparathyroidism who are 
not suitable candidates for parathyroidectomy (9). It 
is also indicated for the treatment of hypercalcemia in 
patients with parathyroid carcinoma. CaSR binding 
by cinacalcet results in decreased PTH secretion 
and synthesis, and it inhibits kidney 1,25 vitamin D 
synthesis and calcium reabsorption; in addition, it 
seems to have an anabolic effect on bone formation (9). 
Possibly because of high levels of a putative PTH-rp 
like peptide, the synthesis of 1,25 vitamin D was not 
affected in the above described patient during the 
cinacalcet treatment; however, it normalized when the 
patient was administered sunitinib. In murine models 
of Leydig cell and colon tumors, cinacalcet attenuated 
hypercalcemia without affecting the synthesis of 
PTR-rp mRNA by the tumor. This effect occurred 
in a dose-dependent manner independently from 
the PTH-rp administration in parathyroidectomized 
animals (10). Furthermore, these studies suggest 
that cinacalcet mediates the reduction in calcium 
levels, at least partially, by stimulating the release of 
calcitonin by C-cells. Another possible mechanism 
yet to be investigated could be the calcium lowering 
effect of cinacalcet through enhanced renal excretion 
of calcium (10). 
Hypophosphatemia is also related to HCM, namely 
the decrease of renal reabsorption of phosphates, 
likely due to a PTH-rp-induced effect. In our case 
report, cinacalcet normalized low phosphates levels, as 
previously described in mouse models of HCM treated 
with cinacalcet. This effect has been attributed to an 
inhibitory effect of calcimimetics on phosphaturic 
hormones such as FGF-23 (9,10).
To the best of our knowledge, the hypocalcemic 
effects of cinacalcet have never been documented 
in pancreatic neuroendocrine tumor patients. The 
clinical case we have described is the second case in the 
literature in which cinacalcet was used successfully to 
treat refractory HCM. A previous report described a 
57-year-old male with hypercalcemia and a pulmonary 
tumor secreting PTH-rp (11). In that case, the patient’s 
calcium and PTH-rp levels decreased during combined 
chemotherapy and cinacalcet monotherapy. When 
hypercalcemia recurred after the fourth chemotherapy 
cycle, cinacalcet monotherapy induced a consistent 
decline in PTH-rp levels, thus preventing a further 
increase in serum calcium levels (11). 
Sunitinib is an oral, multi-target, tyrosine kinase 
inhibitor used to treat GIST, advanced renal cell 
carcinomas, and advanced pancreatic neuroendocrine 
tumors. A calcium-lowering effect of this drug was 
observed in a case of metastatic renal cell carcinoma 
and paraneoplastic hypercalcaemia (12). The 
authors observed that there was no reported case of 
paraneoplastic hypercalcemia recovery with targeted 
therapy until their report. We are unaware of any 
report, thus far, that describes the hypocalcemic effect 
of sunitinib in pNET patients.
In the clinical case reported here, the combined use 
of cinacalcet and sunitinib decreased the patient’s serum 
calcium levels to low-normal levels and normalized the 
PTH concentration. Although chemotherapy initially 
controlled the calcium levels at upper normal levels, 
the combined treatment induced a strong calcium 
lowering effect twice. After the commencement of 
combined cinacalcet + sunitinib treatment, the calcium 
levels were significantly lower compared to when 
the patient was undergoing cytotoxic chemotherapy. 
Moreover, the combined cinacalcet + sunitinib 
treatment resulted in a dramatic drop of calcium levels 
(i.e., hypocalcaemia) and induced the occurrence of 
secondary hyperparathyroidism.
CONCLUSIONS
This case report describes the unusual association 
of malignant pNET-associated hypercalcemia, high 
1,25 OH vitamin D, and high calcitonin levels. 
Several treatments options for the management of 
hypocalcaemia have been unsuccessfully attempted, 
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Cinacalcet demonstrated a definite calcium lowering 
effect and improved the clinical condition of the 
patient. Thus, we believe that cinacalcet can enrich the 
pharmacological armamentarium for the treatment of 
HCM. Moreover, sunitinib helped to normalize the 
patient’s calcium and calcitonin levels, with modest 
tumor shrinkage. The precise mechanism of the 
calcium lowering effect of sunitinib remains to be 
elucidated. In conclusion, here, we report for the first 
time the successful use of cinacalcet and sunitinib in the 
management of pNET-associated HCM.
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